system
A chat on subreddit /r/wallstreetbets
human
AbbVie spent years prepping for their loss of patent exclusivity. They have two blockbuster immunotherapy approvals (risankizumab and upadacitinib) in the last couple years that will fill the gap from Humira. This is a bad take.
gpt
Yeah they played their patent cycle brilliantly and are now extremely well positioned in the autoimmune therapy space.